Tenaya Therapeutics Inc (TNYA)
4.42
+0.24
(+5.74%)
USD |
NASDAQ |
May 22, 16:00
4.42
0.00 (0.00%)
After-Hours: 20:00
Tenaya Therapeutics Cash from Financing (TTM): 51.32M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 51.32M |
December 31, 2023 | 4.049M |
September 30, 2023 | 81.16M |
June 30, 2023 | 81.17M |
March 31, 2023 | 77.25M |
December 31, 2022 | 77.77M |
September 30, 2022 | 0.26M |
Date | Value |
---|---|
June 30, 2022 | 190.53M |
March 31, 2022 | 188.97M |
December 31, 2021 | 208.97M |
September 30, 2021 | 294.92M |
June 30, 2021 | 135.34M |
March 31, 2021 | 136.61M |
December 31, 2020 | 147.27M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
0.26M
Minimum
Sep 2022
294.92M
Maximum
Sep 2021
119.68M
Average
108.25M
Median
Cash from Financing (TTM) Benchmarks
Biomarin Pharmaceutical Inc | -20.78M |
Corvus Pharmaceuticals Inc | 7.851M |
Solid Biosciences Inc | 110.36M |
Dyne Therapeutics Inc | 433.90M |
Sana Biotechnology Inc | 217.81M |